A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: No Interventions, No intervention.
- Кому может быть актуально
- Состояния в реестре: Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Великобритания
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
Подробное описание
This study will be looking at the measurement of body mass composition using bioimpedance analysis (BIA) and quadriceps muscle ultrasound in patients with fibrotic lung disease who are on anti-fibrotic drugs. These anti-fibrotic drugs (nintedanib and pirfenidone) commonly cause gastrointestinal side effects such nausea, loss of appetite and diarrhoea. As a result of these side effects some patients may have a change in the amount of body fat and muscle. This change is not able to be identified using weight or body mass index (BMI). BIA machines are a quick and easy method of looking at body mass composition and require patients to have electrodes attached to their body for approximately 6 seconds. BIA machines are already in routine care for patients with other types of lung conditions. Using muscle ultrasound we will be able to measure the size of the muscle in the thigh.
In addition to the use and tolerability of BIA and muscle ultrasound in this group of patients we will be also taking other measurements including mid-arm circumference and physical tests (sitting to standing, walking speed and muscle strength). We will also use questionnaires to ask about symptoms relating to quality of life, physical activity and gastrointestinal symptoms. Patients will also provide a 3-day diet diary. We will be performing all of the above tests at the beginning before patients start the anti-fibrotic drugs and then again 4 months after starting the drugs and assessing for any changes over this period of time.
Вмешательства
- Другое No Interventions
No intervention - Другое No intervention
No intervention
Первичные конечные точки
- Recruitment of patients to study [Срок оценки: For study recruitment window of 6 months]
- Implementation of study protocol [Срок оценки: For the 6 month recruitment window]
- Feasibility of collection of data [Срок оценки: For the the study recruitment window of 6 months]
- Acceptability of use of BIA and muscle ultrasound [Срок оценки: To be performed at baseline visit and 4 month visit]
Вторичные конечные точки (10)
- Bioelectrical impedance analysis (BIA) [Срок оценки: Performed at baseline visit and at 4 month visit]
- Five times sit to stand (5TST) [Срок оценки: To be performed at baseline visit and at 4 month visit]
- Four metre gait speed (4MGS) [Срок оценки: To be performed at baseline visit and 4 month visit]
- Questionnaires assessing gastrointestinal symptoms [Срок оценки: To be performed at baseline visit and at 4 month visit]
- Questionnaires assessing respiratory symptoms and quality of life [Срок оценки: To be performed at baseline visit and at 4 month visit]
- Questionnaire to assess levels of physical activity [Срок оценки: To be performed at baseline visit and at 4 month visit]
- Muscle strength [Срок оценки: Performed at baseline visit and 4 month visit]
- Height [Срок оценки: To be performed at baseline]
- Body weight [Срок оценки: Performed at baseline visit and 4 month visit]
- Quadriceps ultrasound [Срок оценки: To be performed at baseline visit and 4 month visit]
Критерии участия
Критерии включения
- A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
- Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)
- Subject aged > 18 years
- Able to willingly give consent
Критерии исключения
- Co-morbidities currently requiring enteral feeding
- Weight loss > 10% in preceding 3-6 months
- Significant musculoskeletal issues that may impact muscle mass
- End of life care (expected < 6 weeks left to live)
- Previous anti-fibrotic use
- Currently on > Prednisolone 10mg daily
- Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM)
- Heart failure
- Pregnancy
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Другое
Центры проведения
Великобритания · 1 центр
- Royal Brompton Hospital — London
Идентификаторы
NCT: NCT07332117 · IRAS ID: 358410